Could the Breadcrumb Technique Help Boost Your Landing Page Conversions?

We’ve all heard the term “less is more”. And we’ve been told this applies for landing pages too. I.e. your forms should be short and only ask for only the bare minimum of required information if you want to convert. As an example, one of the main questions someone typically has when faced with a landing page is is how much your offer will cost. But if the offer on your landing page is for a free quote, you can’t necessarily disclose pricing on the page. When there’s no pricing, but instead a form requiring a name, phone number, and email, the visitor knows.

Spotlight

Labcyte Inc.

Labcyte was acquired by Beckman Coulter Life Sciences in January 2019, and Echo liquid handlers and Access workstations are now part of the Beckman Coulter Life Sciences Biotechnology business unit. Since 1935, the Beckman name has been synonymous with technologies that simplify and automate complex biomedical testing. Decades later, our global organization also came to embody the scientific legacy of the Coulter name. Today, Beckman Coulter Life Sciences is a trusted, worldwide resource for tools to help optimize research and manufacturing efficiency.

OTHER ARTICLES
MedTech

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | October 7, 2022

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More
MedTech

Top 3 Biotech Clinical Data Management Trends to Watch in 2022

Article | July 13, 2022

Introduction The administration of medical records and data has advanced significantly during the past few decades. Clinical data management, which was once only a small subset of biotech research organizations, has now developed into a mission-critical, specialized unit. In the late 1990s, electronic data capture (EDC) began to alter the traditional function of clinical data management. After that, the data configuration and management of data queries for the EDC system fell under the purview of clinical data management services. Today, clinical data management is not only responsible for managing the clinical data configuration and data queries but also developing and implementing data administration plans, ensuring data accuracy and completeness, and maintaining optimum data security. In recent years, as digital technologies have gained acceptance around the globe, data has become a vital aspect in decision-making across numerous industries, and the life sciences and biotechnology sectors are no exception. Using data has provided granular insights to biotech organizations, assisting them in creating breakthroughs in drug development and medical research and signifying the importance of clinical trial management systems in these medical verticals. The Biggest Biotech Clinical Data Management Trends to Know About Today The future of clinical data management is contingent upon the implementation of systems and regulations. It is imperative for all organizations participating in a medical or life science trial to have transparent rules in place for sharing and retaining patient data. Also, there is a need to have a standardized format for maintaining these records and documents related to trials. This assists biotech organizations in reducing the chances of ambiguity regarding who owns what kind of data or paperwork at any given time. Over the past couple of years, the focus of the life science and biotechnology industries has shifted towards developing more effective medications and therapies, implementing personalized treatment, and finding cures for diseases such as cancer and AIDS. In response to this, a substantial rise in the number of clinical trials is being witnessed globally. As the number of clinical trials continues to accelerate, the spending on these trials rises as well. In response to this, the worldwide cost of conducting clinical trials is anticipated to reach US$ 49.80 billion in 2022. With the transition of the world from traditional to digital, medical professionals and biotech businesses are increasingly shifting towards adopting high-tech and reliable clinical trial management systems for various applications, starting from diagnosis and clinical trials to patient data documentation. But, what are the future trends in biotechnology clinical data management? Let’s discuss. Cloud-Based Clinical Metadata Repositories Automation is emerging as a new frontier in the biotech clinical data management domain, along with other innovative technologies such as artificial intelligence and machine learning. Because of this, life science establishments are witnessing a huge shift from paper-based documentation toward data-based documentation, which is creating mountains of research, compliance, and clinical data. The growing demand for new and more effective medications and drugs is augmenting the need to expedite clinical trials. This is resulting in an increased number of initiatives aimed at optimizing clinical trial processes to prepare and launch successful trials. However, pharmaceutical and biotechnology laboratories are encountering several challenges in collecting, managing, and analyzing metadata due to its complexities. So, what is the best solution to this problem? The answer to this is cloud-based clinical metadata repositories. Clinical research facilities are leveraging advanced, all-in-one, cloud-based clinical metadata repositories to assist them in centralizing and managing metadata; increasing metadata quality, consistency, and accuracy; and speeding up clinical trial management, documentation, and compliance processes. Shift Towards Digital Solutions Electronic Case Report Form Adequate research and accurate data are crucial for a clinical trial to succeed. Whether developing new drugs, medication, or therapies; conducting life science research; or studying the latest clinical trial systems, it is best to use electronic solutions as it reduces the room for mistakes during the transition of clinical data from paper-based format. Realizing this, biotech organizations are shifting towards using electronic case report forms to speed up record retrieval, improve record security, and cut down on operational costs associated with running clinical trials. The electronic case report form assists in lowering the failure rate of the clinical trial, enhancing efficiency, and optimizing security along with improving clinical trial documentation and productivity, further driving its adoption in the medical space. Electronic Clinical Outcome Assessment Electronic clinical outcome assessment is surfacing as one of the fast-growing future trends in biotechnology. It allows clinical trial facilities to automate data entry and improve the reliability of the collected information. The technology enables clinical trial institutions to automatically record patient-provided information about side effects, symptoms, drug timing, and other aspects during the clinical trial for increased precision. It also helps these institutions analyze the results of medication or therapy in clinical trials and lets clinical researchers use medical technologies like biosensor-enabled devices, self-service applications, and medical wearables for evaluation. Hence, biotech clinical facilities are increasingly deploying advanced electronic clinical outcome assessment systems to ensure adherence to protocols and regulations. Clinical Trial Customization The success of a new drug is determined by numerous factors other than its effectiveness, safety, and creativity of its developers, such as a successful clinical trial. Each clinical trial involves a number of decision-making points, and one wrong choice in any of these aspects can jeopardize the success of the entire endeavor. A crucial component of making well-informed decisions is data management, which is a part of clinical study as a whole. Clinical trial customization is emerging as one of the most prominent biotech clinical trial management trends. Every clinical trial is unique and needs a tailored approach to be successful. With the emergence of the trend of personalized treatment around the globe, biotech and pharmaceutical organizations are adopting innovative customized clinical trial management solutions to accelerate the pace of clinical trials and approvals. This is giving clinical researchers innovative ways to come up with new medicines for patients and streamline the clinical data as per the requirements for faster approvals. What Are the Key Clinical Data Management Challenges Faced by Biotech Companies? Groundbreaking medical interventions are of no use without reliable, accurate, and extensive clinical trial data. Without the data, biotech and pharmaceutical companies will not be able to provide the assurance of safety and efficacy required to bring the medication to market. Regulatory bodies such as the Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and others are putting stricter rules in place to ensure the quality of clinical data. In addition, the fast-changing clinical development environment is creating more obstacles for biotech and medical spaces to ensure the accuracy, standard, and completeness of the clinical trial data. Hence, clinical teams are spending valuable time cleaning up data instead of analyzing it. Time spent trying to figure out issues with clinical trial data is detrimental and expensive but also mission-critical. This is because a small issue in the data can lead to numerous consequences, from small delays to calamitous setbacks, making it necessary to rerun clinical trials. This problem will only get more challenging to address as the volume of data and the types of data sources continue to grow. Here are some of the major clinical data management challenges that biotech firms encounter Standardization of Clinical Metadata Stringent Regulatory Compliance Increased Clinical Trial Complexity Mid-Study Changes Why Are Clinical Data Management Systems Garnering Popularity in the Biotech Industry? With the changing regulatory and clinical landscape, biotech and pharmaceutical companies are facing several obstacles in the management of clinical data and clinical trials. In addition, regulatory agencies are moving toward integrated electronic systems, which is making it more and more important for clinical laboratories to change the format of their submissions. Because of this, several biotech clinical labs are focusing on adopting innovative laboratory solutions, such as biotech clinical data management systems, to meet the need for standardized data inputs and replace all manual ways of working with electronic systems. A clinical data management system establishes the framework for error-free data collection and high-quality data submission, resulting in speedier drug discovery and shorter time-to-market. These solutions are gaining huge traction among biotech and pharmaceutical companies, owing to their ability to effectively manage clinical data, accelerate clinical trials, and ensure compliance. Let’s see some of the features of biotech clinical data management software that are most sought after by life-science companies Controlled, standardized data repository. Centralized data analysis and administration. Reduced operational expenditures for clinical data processes. Enhanced process effectiveness. Superior submission quality Compliance with predefined standards. Clinical Data Management Systems: The Future The role of clinical data management systems is evolving at a rapid pace as the life science and medical industries continue to incorporate digital solutions for diverse operations. These systems are being used in a variety of biotech clinical settings, ranging from clinical data compliance to data science and analytics, to help them analyze large and growing volumes of clinical data. Hence, a number of high-tech medical companies are aiming at integrating innovative technologies, such as artificial intelligence and machine learning, into clinical data management software to automate clinical data management tasks, improve clinical data submission, and enhance data quality. These new biotech clinical management technologies are anticipated to help life science laboratories gain a better understanding of diseases and speed up clinical trials in the coming years. FAQ What is a clinical data management system? A clinical data management system (CDMS) is a tool used in clinical research to track, record, and manage clinical trial data across medical establishments such as biotech laboratories. What are the key functions of the biotech clinical data management system? Some of the key functions of biotech clinical data management system are Documentation of Protocols and Regulations Patient Recruitment Real-time Clinical Study Analytics Reporting Investigator Relationship Management Electronic Visit Report Why is a clinical data management system needed for clinical trials today? A clinical data management system helps shorten the time from drug development to marketing by assisting in the collection of high-quality, statistically sound, and accurate data from clinical trials.

Read More
MedTech

Making Predictions by Digitizing Bioprocessing

Article | September 22, 2022

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More
Medical

Nanostructures: Emerging as Effective Carriers for Drug Delivery

Article | July 14, 2022

Natural remedies have been employed in medicine since antiquity. However, a large number of them fail to go past the clinical trial stages. In vivo instability, poor solubility and bioavailability, a lack of target-specific delivery, poor absorption, and side effects of the medication are only a few of the problems caused by the use of large-sized materials in drug administration. Therefore, adopting novel drug delivery systems with targeted medications may be a solution to address these pressing problems. Nanotechnology has received tremendous attention in recent years and has been demonstrated to help blur the boundaries between the biological and physical sciences. With great success, it plays a vital part in enhanced medication formulations, targeted venues, and controlled drug release and delivery. Limitations of Traditional Delivery Trigger the Adoption of Nanoparticles The field of nanotechnology and the creation of drug formulations based on nanoparticles is one that is expanding and showcasing great potential. It has been thoroughly researched in an effort to develop new methods of diagnosis and treatment and to overcome the limitations of several diseases' current therapies. As a result, nanoparticles are being used to improve the therapeutic effectiveness and boost patient adherence to treatment by increasing medication bioavailability, drug accumulation at a particular spot, and reducing drug adverse effects. The nanoparticles could be transformed into intelligent systems housing therapeutic and imaging agents by manipulating their surface properties, size, correct drug load, and release with targeted drug delivery. Nanostructures facilitate the release of combination medications at the prescribed dose since they remain in the blood circulation system for a long time. Therefore, they result in fewer plasma fluctuations with decreased side effects. Due to their nanoscale, these structures can easily enter the tissue system, promote the absorption of drugs by cells, make medication administration more effective, and ensure that the medicine acts at the targeted location. The Way Ahead Nanomedicine and nano-delivery systems are a comparatively new but fast-evolving science in which nanoscale materials are used as diagnostic tools to deliver drug molecules at precisely targeted sites in a controlled manner. It is finding applications for the treatment of diseases such as cardiovascular, neurodegenerative, cancer, ocular, AIDS, and diabetes, among others. With more research and technological advancement, these drug delivery solutions will open up huge opportunities for companies that work with them.

Read More

Spotlight

Labcyte Inc.

Labcyte was acquired by Beckman Coulter Life Sciences in January 2019, and Echo liquid handlers and Access workstations are now part of the Beckman Coulter Life Sciences Biotechnology business unit. Since 1935, the Beckman name has been synonymous with technologies that simplify and automate complex biomedical testing. Decades later, our global organization also came to embody the scientific legacy of the Coulter name. Today, Beckman Coulter Life Sciences is a trusted, worldwide resource for tools to help optimize research and manufacturing efficiency.

Related News

Global Search Marketing Agency, Directive, Announces Complete Rebranding

Directive Consulting | December 05, 2018

Directive, the leading B2B and enterprise search marketing agency, announced today the launch of their new branding to reflect their evolution into a global search marketing agency. Directive’s unique approach to search marketing has positioned the company as the agency of choice for leading B2B and enterprise companies since 2014 with a portfolio comprised of 90% in the B2B space. With their extensive rebranding efforts, the company continues to offer premier SEO, PPC, CRO, content marketing and paid social services that B2B and enterprises need to scale their business. Additionally, Directive continues to invest further in employee well-being, marketing technologies and superior support for clients. “Our rebranding does not impact our services, operations or our market, as we have been working with leaders in the B2B space for some time; however, our identity now reflects and matches that,” stated Hannah Mans, Directive’s director of marketing. “This milestone is the first of many as we work towards our vision to be the largest global B2B search agency by the end of 2020.” The rebranding includes a top-to-bottom redesign of the company’s website and logo to better resonate with current and potential clients.

Read More

Directive Ranks #1 in Clutch’s Top B2B Marketing Service Providers

Directive Consulting | March 06, 2019

Directive, the leading B2B and enterprise search marketing agency, has recently been honored as the number one B2B marketing and advertising service provider in Los Angeles, according to Clutch. Clutch is a B2B research, ratings and reviews site that identifies leading IT and marketing service providers and software. Recently, Clutch has announced over 260 B2B companies that embody industry leadership in Los Angeles based on their market presence, respective expertise, verified client feedback, and their past and current clientele. Directive was awarded the leading spot on the advertising and marketing list. “We are thrilled for this opportunity to be recognized as the go-to service provider for B2B marketing,” said CEO and Co-founder Garrett Mehrguth. “This is a testament to our team’s dedication and unwavering focus on excellence and to deliver premier services to our clients.” Since its establishment in 2014, Mehrguth has led Directive in its expansion of five global offices including Orange County, California; Austin, Texas; Los Angeles; New York City; and London. Directive has increased by a year-over-year growth rate of 300 percent, and now is celebrating as the number one B2B marketing and advertising service provider in Los Angeles.

Read More

27-year-old Search Marketing CEO Lands 13-stop U.S. Speaking Tour

Directive Consulting | May 29, 2019

Garrett Mehrguth, the CEO and co-founder of the B2B and enterprise search marketing agency, Directive, recently was selected to speak at 13 stops of the Digital Summit tour. Digital Summit, the largest conference series in the digital marketing industry, has invited Mehrguth to share his unique presentation, "5 Data-Validated Tactics to Increase the Experienced Marketer's Qualified Lead Volume (...and 3 Tactics That Are Guaranteed to Fail)" with their audiences across the nation. Mehrguth will continue to discuss how B2B and enterprise marketers can advance their digital "discoverability" and take control of their residency on search engine results pages. This approach has catalyzed Directive's growth by 300 percent year-over-year. It also is the foundation that the firm's strategies are built on, which is utilized across their portfolio of over 75 clients. "I've had the pleasure of working with Garrett over the past year, as he has proven to be a stand-out speaker in our Digital Summit Series," said Leah Harris, content and product strategist for Digital Summit. "We curate 20 marketing conferences with over 1,000 speakers in total, and Garrett consistently engages the crowd with his expertise and surveys in the top 20 percent of speakers."

Read More

Global Search Marketing Agency, Directive, Announces Complete Rebranding

Directive Consulting | December 05, 2018

Directive, the leading B2B and enterprise search marketing agency, announced today the launch of their new branding to reflect their evolution into a global search marketing agency. Directive’s unique approach to search marketing has positioned the company as the agency of choice for leading B2B and enterprise companies since 2014 with a portfolio comprised of 90% in the B2B space. With their extensive rebranding efforts, the company continues to offer premier SEO, PPC, CRO, content marketing and paid social services that B2B and enterprises need to scale their business. Additionally, Directive continues to invest further in employee well-being, marketing technologies and superior support for clients. “Our rebranding does not impact our services, operations or our market, as we have been working with leaders in the B2B space for some time; however, our identity now reflects and matches that,” stated Hannah Mans, Directive’s director of marketing. “This milestone is the first of many as we work towards our vision to be the largest global B2B search agency by the end of 2020.” The rebranding includes a top-to-bottom redesign of the company’s website and logo to better resonate with current and potential clients.

Read More

Directive Ranks #1 in Clutch’s Top B2B Marketing Service Providers

Directive Consulting | March 06, 2019

Directive, the leading B2B and enterprise search marketing agency, has recently been honored as the number one B2B marketing and advertising service provider in Los Angeles, according to Clutch. Clutch is a B2B research, ratings and reviews site that identifies leading IT and marketing service providers and software. Recently, Clutch has announced over 260 B2B companies that embody industry leadership in Los Angeles based on their market presence, respective expertise, verified client feedback, and their past and current clientele. Directive was awarded the leading spot on the advertising and marketing list. “We are thrilled for this opportunity to be recognized as the go-to service provider for B2B marketing,” said CEO and Co-founder Garrett Mehrguth. “This is a testament to our team’s dedication and unwavering focus on excellence and to deliver premier services to our clients.” Since its establishment in 2014, Mehrguth has led Directive in its expansion of five global offices including Orange County, California; Austin, Texas; Los Angeles; New York City; and London. Directive has increased by a year-over-year growth rate of 300 percent, and now is celebrating as the number one B2B marketing and advertising service provider in Los Angeles.

Read More

27-year-old Search Marketing CEO Lands 13-stop U.S. Speaking Tour

Directive Consulting | May 29, 2019

Garrett Mehrguth, the CEO and co-founder of the B2B and enterprise search marketing agency, Directive, recently was selected to speak at 13 stops of the Digital Summit tour. Digital Summit, the largest conference series in the digital marketing industry, has invited Mehrguth to share his unique presentation, "5 Data-Validated Tactics to Increase the Experienced Marketer's Qualified Lead Volume (...and 3 Tactics That Are Guaranteed to Fail)" with their audiences across the nation. Mehrguth will continue to discuss how B2B and enterprise marketers can advance their digital "discoverability" and take control of their residency on search engine results pages. This approach has catalyzed Directive's growth by 300 percent year-over-year. It also is the foundation that the firm's strategies are built on, which is utilized across their portfolio of over 75 clients. "I've had the pleasure of working with Garrett over the past year, as he has proven to be a stand-out speaker in our Digital Summit Series," said Leah Harris, content and product strategist for Digital Summit. "We curate 20 marketing conferences with over 1,000 speakers in total, and Garrett consistently engages the crowd with his expertise and surveys in the top 20 percent of speakers."

Read More

Events